EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Disarming carbapenemase-producing Acinetobacter baumannii : high potency of the novel therapeutic combination of meropenem and the innovative diazabicyclooctane β-lactamase inhibitor pilabactam (formerly ANT3310)

Salud Rodríguez-Pallares iD, Michelle Outeda-García iD, Emilio Lence, Arianna Rodríguez-Coello, Lucía González-Pinto iD, Paula Guijarro-Sánchez, Gabriela Alejandra Báez-Barroso, Tania Blanco-Martín iD, Juan Carlos Vázquez-Ucha, Agustina Llanos, Filomena Sannio, Jean-Denis Docquier iD und 8 weitere

Antimicrobial Agents and Chemotherapy · 01.04.2026 · 70 (4)

DOI: 10.1128/aac.01691-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 01.04.2026. Verfasst von Salud Rodríguez-Pallares und 19 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Microbiología Clínica & Grupo de Investigación en Microbiología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hosp…. Hauptthemen laut MEDLINE: Acinetobacter baumannii, beta-Lactamase Inhibitors, beta-Lactamases, Anti-Bacterial Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Xunta de Galicia, Centro Singular de Investigación de Galicia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Carbapenem-resistant Acinetobacter baumannii (CRAB) represents an urgent global health threat, with resistance primarily driven by carbapenem-hydrolyzing class D β-lactamases (CHDLs) such as OXA-23. Therapeutic options remain limited due to the scarcity of effective β-lactam/β-lactamase inhibitor combinations. Pilabactam (formerly ANT3310) is a novel diazabicyclooctane (DBO) β-lactamase inhibitor featuring a fluorine substituent that extends its activity spectrum, relative to approved DBOs like avibactam and relebactam, to include CHDLs. Pilabactam is currently in phase I clinical trials in combination with meropenem, and its activity and mechanism against CRAB remain incompletely defined. Using engineered A. baumannii strains producing individual β-lactamases, we show that pilabactam restores meropenem activity against serine β-lactamase producers, including difficult-to-inhibit CHDLs. This was corroborated in 68 whole-genome-sequenced meropenem-resistant clinical isolates, yielding MIC₅₀ and MIC₉₀ values for meropenem/pilabactam of 1 and 2 mg/L, respectively. Frequency of resistance studies in representative CHDL producers demonstrated suppression of resistance selection at 4× MIC. Kinetic analyses revealed that pilabactam inhibits OXA-23 via a two-step tight binding mechanism, with slightly higher inactivation rates (1.7 × 10⁴ M⁻¹s⁻¹) than that of durlobactam (3.5 × 10³ M⁻¹s⁻¹). Pilabactam also yielded a low dissociation constant ( K d ≈ 4 nM) and slow off-rate, indicating durable inhibition. Molecular dynamics simulations revealed the critical role of the fluorine substituent in forming stabilizing hydrogen-bonding and CH–F interactions within the tunnel-like OXA-23 active site. These findings identify pilabactam as a potent novel DBO supporting its development with meropenem for treating CRAB infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acinetobacter baumanniibeta-Lactamase Inhibitorsbeta-LactamasesAnti-Bacterial AgentsBacterial ProteinsAzabicyclo CompoundsThienamycinsMeropenemMicrobial Sensitivity Tests

Stichwörter der Autor:innen

ANT3310Acinetobacter baumanniiOXA-23carbapenem resistancecarbapenemspilabactamβ-lactamaseβ-lactamase inhibitors

Substanzen

Meropenembeta-Lactamase Inhibitorsbeta-LactamasesAnti-Bacterial AgentsBacterial ProteinsAzabicyclo CompoundscarbapenemaseThienamycins

Autor:innen und Institutionen

  • Servicio de Microbiología Clínica & Grupo de Investigación en Microbiología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Co…
  • CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
  • Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, Santiago de Compostela, Spain.
  • Departamento de Química Orgánica, Facultad de Ciencias, Universidad de Valladolid, Campus Miguel Delibes, Valladolid, Spain.
  • Antabio SAS, Labège, France.
  • Dipartimento di Biotecnologie Mediche, Università degli Studi di Siena, Siena, Italy.

ORCID-Profile: Salud Rodríguez-Pallares, Michelle Outeda-García, Lucía González-Pinto, Tania Blanco-Martín, Jean-Denis Docquier, Germán Bou, Alejandro Beceiro, Jorge Arca-Suárez

Förderung

  • Instituto de Salud Carlos III
  • Xunta de Galicia
  • Centro Singular de Investigación de Galicia
  • Italian Ministry of University and Research and the European Union
  • Agencia Estatal de Investigación

Zitieren

APA

Rodríguez-Pallares, S., Outeda-García, M., Lence, E., Rodríguez-Coello, A., González-Pinto, L., Guijarro-Sánchez, P., Báez-Barroso, G. A., Blanco-Martín, T., Vázquez-Ucha, J. C., Llanos, A., Sannio, F., Docquier, J. D., Morrisey, I., Hawser, S., Zalacain, M., Lemonnier, M., González-Bello, C., Bou, G., Beceiro, A., & Arca-Suárez, J. (2026). Disarming carbapenemase-producing Acinetobacter baumannii : high potency of the novel therapeutic combination of meropenem and the innovative diazabicyclooctane β-lactamase inhibitor pilabactam (formerly ANT3310). Antimicrobial Agents and Chemotherapy, 70(4). https://doi.org/10.1128/aac.01691-25

Vancouver

Rodríguez-Pallares S, Outeda-García M, Lence E, Rodríguez-Coello A, González-Pinto L, Guijarro-Sánchez P, et al. Disarming carbapenemase-producing Acinetobacter baumannii : high potency of the novel therapeutic combination of meropenem and the innovative diazabicyclooctane β-lactamase inhibitor pilabactam (formerly ANT3310). Antimicrobial Agents and Chemotherapy. 2026;70(4). doi:10.1128/aac.01691-25

BibTeX
@article{RodrguezPallares2026,
  author = {Rodríguez-Pallares, Salud and Outeda-García, Michelle and Lence, Emilio and Rodríguez-Coello, Arianna and González-Pinto, Lucía and Guijarro-Sánchez, Paula and Báez-Barroso, Gabriela Alejandra and Blanco-Martín, Tania and Vázquez-Ucha, Juan Carlos and Llanos, Agustina and Sannio, Filomena and Docquier, Jean-Denis and Morrisey, Ian and Hawser, Stephen and Zalacain, Magdalena and Lemonnier, Marc and González-Bello, Concepción and Bou, Germán and Beceiro, Alejandro and Arca-Suárez, Jorge},
  title = {Disarming carbapenemase-producing Acinetobacter baumannii : high potency of the novel therapeutic combination of meropenem and the innovative diazabicyclooctane β-lactamase inhibitor pilabactam (formerly ANT3310)},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {4},
  doi = {10.1128/aac.01691-25}
}
Kostenlos starten →